(Q44415297)

2 December 2017

Use of arsenic trioxide (As2O3) in the treatment of patients with acute promyelocytic leukemia: the M. D. Anderson experience (English)

1 reference

acute promyelocytic leukemia

2 December 2017

1 reference

1 reference

2

Hagop Kantarjian

1 reference

2 December 2017

6

Jorge Cortes

1 reference

2 December 2017

5

Susan O'Brien

1 reference

2 December 2017

3

Elihu Estey

1 reference

2 December 2017

Guillermo Lazo

1

1 reference

PubMed ID

12712474

2 December 2017

Deborah Thomas

series ordinal

4

1 reference

PubMed ID

12712474

2 December 2017

language of work or name

English

0 references

publication date

1 May 2003

1 reference

2 December 2017

1 reference

2 December 2017

97

1 reference

2 December 2017

9

1 reference

2 December 2017

2218-2224

1 reference

The unique aspects of acute promyelocytic leukemia

2 December 2017

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11314

7 January 2021

Acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11314

7 January 2021

All-trans retinoic acid significantly increases 5-year survival in patients with acute promyelocytic leukemia: long-term follow-up of the New York study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11314

7 January 2021

All-trans retinoic acid followed by chemotherapy for salvage of refractory or relapsed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11314

7 January 2021

Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11314

7 January 2021

United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11314

7 January 2021

Differentiation Therapy of Acute Promyelocytic Leukemia with Tretinoin (All-trans-Retinoic Acid)

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11314

7 January 2021

Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11314

7 January 2021

Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11314

7 January 2021

Combined effect of all-trans retinoic acid and arsenic trioxide in acute promyelocytic leukemia cells in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11314

7 January 2021

The induction of apoptosis and cell cycle arrest by arsenic trioxide in lymphoid neoplasms

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11314

7 January 2021

Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11314

7 January 2021

Effect of arsenic trioxide on viability, proliferation, and apoptosis in human megakaryocytic leukemia cell lines

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11314

7 January 2021

Retinoic acid syndrome induced by arsenic trioxide in treating recurrent all-trans retinoic acid resistant acute promyelocytic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11314

7 January 2021

Torsades de pointes in 3 patients with leukemia treated with arsenic trioxide.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11314

7 January 2021

Sudden death among patients with acute promyelocytic leukemia treated with arsenic trioxide

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.11314

7 January 2021

Identifiers

DOI

10.1002/CNCR.11314

1 reference

2 December 2017

1 reference

PubMed ID

12712474